Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Kom op tegen Kanker
This publication has 25 references indexed in Scilit:
- Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: A systematic review and meta-analysisEJC Skin Cancer, 2025
- A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)European Journal of Cancer, 2022
- c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysisEuropean Journal of Cancer, 2021
- Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imagingCancer Letters, 2019
- Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialThe Lancet Oncology, 2017
- Genomic Classification of Cutaneous MelanomaCell, 2015
- Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancerInternational Journal of Cancer, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009